These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 6634746)
21. Some drug-resistant models for cancer chemotherapy. Part 1: Cycle-nonspecific drugs. Usher JR; Henderson D IMA J Math Appl Med Biol; 1996 Jun; 13(2):99-126. PubMed ID: 8671582 [TBL] [Abstract][Full Text] [Related]
22. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121 [TBL] [Abstract][Full Text] [Related]
23. Mechanisms of drug resistance in breast cancer. Dalton WS Semin Oncol; 1990 Aug; 17(4 Suppl 7):37-9. PubMed ID: 2200130 [TBL] [Abstract][Full Text] [Related]
24. Gains of 1q21-q22 and 13q12-q14 are potential indicators for resistance to cisplatin-based chemotherapy in ovarian cancer patients. Kudoh K; Takano M; Koshikawa T; Hirai M; Yoshida S; Mano Y; Yamamoto K; Ishii K; Kita T; Kikuchi Y; Nagata I; Miwa M; Uchida K Clin Cancer Res; 1999 Sep; 5(9):2526-31. PubMed ID: 10499629 [TBL] [Abstract][Full Text] [Related]
25. Modes of resistance to antitumor agents. Kessel D In Vivo; 1994; 8(5):829-34. PubMed ID: 7727732 [TBL] [Abstract][Full Text] [Related]
26. Adjuvant breast cancer therapy: current status and future strategies--growth kinetics and the improved drug therapy of breast cancer. Norton L Semin Oncol; 1999 Feb; 26(1 Suppl 3):1-4. PubMed ID: 10203263 [TBL] [Abstract][Full Text] [Related]
27. Induction chemotherapy: to downgrade aggressive cancers to improve curability by surgery and/or radiotherapy. Stephens FO Eur J Surg Oncol; 2001 Nov; 27(7):672-88. PubMed ID: 11669597 [TBL] [Abstract][Full Text] [Related]
28. [Drug therapy in bronchial carcinoma]. Manegold C; Drings P Schweiz Med Wochenschr; 1995 Jul; 125(29):1396-405. PubMed ID: 7545824 [TBL] [Abstract][Full Text] [Related]
29. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate. Piver MS Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011 [TBL] [Abstract][Full Text] [Related]
30. Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors. Pentheroudakis G; Fountzilas G; Kalofonos HP; Golfinopoulos V; Aravantinos G; Bafaloukos D; Papakostas P; Pectasides D; Christodoulou C; Syrigos K; Economopoulos T; Pavlidis N; Crit Rev Oncol Hematol; 2008 Jun; 66(3):237-47. PubMed ID: 18243010 [TBL] [Abstract][Full Text] [Related]
31. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer. Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872 [TBL] [Abstract][Full Text] [Related]
32. A novel combination chemotherapy integrating with intratumoral chemotherapy. Yang L; Wang B; Qiao W; Liu P Med Hypotheses; 2009 Sep; 73(3):334-5. PubMed ID: 19423239 [TBL] [Abstract][Full Text] [Related]
33. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
34. Drug resistance in chemotherapy for breast cancer. Saeki T; Tsuruo T; Sato W; Nishikawsa K Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():84-9. PubMed ID: 16273361 [TBL] [Abstract][Full Text] [Related]
35. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Goldie JH; Coldman AJ Cancer Res; 1984 Sep; 44(9):3643-53. PubMed ID: 6744284 [TBL] [Abstract][Full Text] [Related]
36. Stochastic modeling of drug resistance in cancer. Komarova N J Theor Biol; 2006 Apr; 239(3):351-66. PubMed ID: 16194548 [TBL] [Abstract][Full Text] [Related]
37. Additive effects of TRAIL and paclitaxel on cancer cells: implications for advances in cancer therapy. Odoux C; Albers A Vitam Horm; 2004; 67():385-407. PubMed ID: 15110187 [TBL] [Abstract][Full Text] [Related]
38. DNA repair and resistance to chemotherapy. Harris AL Cancer Surv; 1985; 4(3):601-24. PubMed ID: 3916657 [TBL] [Abstract][Full Text] [Related]
39. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein. Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680 [TBL] [Abstract][Full Text] [Related]
40. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review). Boulikas T; Vougiouka M Oncol Rep; 2004 Mar; 11(3):559-95. PubMed ID: 14767508 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]